Masimo (MASI) Gets FDA Nod For RRp Monitoring Technology
Zacks Investment Research | Mar 02, 2020 09:43PM ET
Masimo Corporation (NASDAQ:MASI) recently obtained FDA clearance for the continuous RRp (respiration rate from the photoplethysmograph) monitoring of adult and pediatric patients with Rad-97, Radical-7 and Radius-7 Pulse CO-Oximeters.
With this go-ahead, both continuous and spot-check RRp are now commercially available in the United States. It is supported by a wide range of pulse oximetry sensors and configurations, including the new non-cabled, tetherless, wearable Radius PPG.
The FDA clearance of this monitoring system is expected to strengthen the company’s portfolio of pulse oximetry technologies.
More About the RRp Monitoring
The availability of continuous RRp perfectly complements Masimo’s diverse portfolio of respiration rate monitoring modalities that consists of acoustic respiration rate (RRa), NomoLinecapnography (RRc) and now, photoplethysmographic respiration rate (RRp).
Acoustic respiration rate, RRa, has been proved to be a precise, reliable and convenient method of monitoring respiration rate on a continuous basis. However, in situations where RRa or RRc is not available, RRp offers a convenient way to precisely obtain RR for patients whose arterial oxygen saturation (SpO2) is already being monitored using Masimo SET. RRp is particularly designed to adapt to lower acuity settings like the general ward, where there is a scarcity of respiration rate monitoring technologies for patients.
The availability of RRp should be instrumental in aiding physicians and public health officials to combat respiratory-related illnesses, including the COVID-19, especially when using an additional sensor is not an option.
Alongside RRp, Masimo SET sensors offer Measure-through Motion and Low Perfusion SET pulse oximetry, which has been clinically proven to be superior to other pulse oximetry technologies in more than 100 independent and objective studies.
Market Prospects
Per Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.